ArticleMolecular and cellular biochemistry2026
Bone marrow fibrocytes and endothelial-to-mesenchymal transition drive pathological ECM remodeling in proliferative diabetic retinopathy.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proliferative diabetic retinopathy (PDR) is characterized by pathological neovascularization and fibrovascular membrane (FVM) formation, yet the cellular origins of fibroblasts within FVMs and vitreous collagen metabolism remain poorly understood. Vitreous humor and FVM specimens were collected from PDR patients and non-diabetic controls undergoing vitrectomy. Immunohistochemistry, enzyme-linked immunosorbent assay (ELISA), and enzymatic activity assays were performed. Double-positive staining for cluster of differentiation (CD)45/collagen type I (COL1) and CD45/S100 calcium-binding protein A4 (S100A4) identified bone marrow-derived fibrocytes, while CD31/COL1 co-expression indicated endothelial-to-mesenchymal transition (EndoMT). Fibronectin was significantly elevated in PDR vitreous (p < 0.01). Matrix metalloproteinase (MMP)-2, MMP-3, and MMP-9 activities were markedly increased in PDR (all P < 0.001), alongside elevated lysyl oxidase (LOX) activity (p < 0.001). Collagen IV detection rates were higher in PDR (63.2% vs. 15%, P < 0.01), and beta cross-linked C-telopeptide of type I collagen (β-CTX) levels were significantly increased (p < 0.001). Notably, total procollagen type I N-terminal propeptide (Total-PINP) was paradoxically elevated in PDR vitreous (p < 0.01), suggesting compensatory collagen synthesis during active neovascularization. These findings demonstrate that FVM fibroblasts originate from multiple sources including bone marrow-derived fibrocytes and EndoMT, and that PDR involves simultaneous MMP-mediated collagen degradation and LOX-mediated cross-linking, providing potential targets for anti-fibrotic therapies.
Indexed as
Identifiers
42622987What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.